Home > Inhibitors & Agonists > Cell Cycle/DNA Damage > DNA/RNA Synthesis
Cat. No. Product name CAS No.
DC4196 Bleomycin Sulfate

Bleomycin sulfate (Blenoxane) is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.

DC7959 BMH-21 Featured

BMH-21 is a small molecule DNA intercalator that binds ribosomal DNA and inhibits RNA polymerase I transcription; does not cause phosphorylation of H2AX.

DC10430 COH29

COH29 is a potent ribonucleotide reductase (RNR) inhibitor with anticancer activity with an IC50 of 8 μM in KB cell.

DC7810 CX-5461 Featured

CX-5461 is an inhibitor of rRNA synthesis, selectively inhibits Pol I-driven transcription of rRNA, has no effect on Pol II, and possesses 250-to 300-fold selectivity for inhibition of rRNA transcription versus DNA replication and protein translation.

DC4197 Actinomycin D

Dactinomycin (also known generically as Actinomycin D ) is the most significant member of actinomycines, which are a class of polypeptide antibiotics isolated from soil bacteria of the genus Streptomyces.

DC7664 Quarfloxin (CX-3543) Featured

Quarfloxin (CX-3543) is a fluoroquinolone derivative with antineoplastic activity.

DC7725 TH 287 Featured

TH 287 is a first-in-class MTH1 inhibitor (IC50 value 5.0 nM) that selectively and effectively kills U2OS and other cancer cell lines, with considerably less toxicity towards several primary or immortalized cells.

DC7726 TH 588 Featured

TH588 is a novel potent, selective and cell permeable inhibitor of the nudix hydrolase family MTH1 protein with an IC50 of ~5 nM.

DC28171 Rifalazil

Rifalazil (KRM-1648; ABI-1648), a rifamycin derivative, inhibits the bacterial DNA-dependent RNA polymerase and kills bacterial cells by blocking off the β-subunit in RNA polymerase. Rifalazil (KRM-1648; ABI-1648) is an antibiotic, exhibits high potency against mycobacteria, gram-positive bacteria, Helicobacter pylori, C. pneumoniae and C. trachomatis with MIC values from 0.00025 to 0.0025 μg/ml. Rifalazil (KRM-1648; ABI-1648) has the potential for the treatment of Chlamydia infection, Clostridium difficile associated diarrhea (CDAD), and tuberculosis (TB).

DC28404 Caracemide

Caracemide (NSC-253272) inhibits the enzyme ribonucleotide reductase of Escherichia coli. Caracemide is a novel anticancer agent derived from a hydroxamic acid and has demonstrated to produce severe central nervous system (CNS) toxicity.

DC28439 Sorivudine

Sorivudine (BV-araU) is an orally active synthetic pyrimidine nucleoside antimetabolite drug. Sorivudine derives its antiviral activity from selective conversion by a specific thymidine kinase present in certain DNA viruses to nucleotides, which can in turn interfere with viral DNA synthesis.

DC28942 T-705RTP sodium

T-705RTP sodium, a nucleotide analog, selectively inhibits RNA-dependent RNA polymerase (RdRp) of the influenza virus. T-705RTP sodium competitively incorporates ATP/GTP and a single molecule of T-705RTP sodium is incorporated into a nascent RNA strand, which then inhibits subsequent virus RNA extension.

DC28948 T-705RTP

T-705RTP is a selective and GTP-competitive influenza virus RNA polymerase inhibitor with an IC50 of 0.14 μM and a Ki of 1.52 μM. T-705RTP is the active triphosphate metabolite of T-705 and has potent anti-influenza virus activity.

Page 1 / Total 1 FirstPrevNextLastGoto